OncoSec Medical (OncoSec Medical) Total Stockholders Equity : $-5.49 Mil (As of Jan. 2023)

View and export this data going back to 1986. Start your Free Trial

What is OncoSec Medical Total Stockholders Equity?

OncoSec Medical's Total Stockholders Equity for the quarter that ended in Jan. 2023 was $-5.49 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. OncoSec Medical's Book Value per Share for the quarter that ended in Jan. 2023 was $-1.85. The ratio of a company's debt over equity can be used to measure how leveraged this company is. OncoSec Medical's Debt-to-Equity for the quarter that ended in Jan. 2023 was -0.63.

OncoSec Medical Total Stockholders Equity Historical Data

The historical data trend for OncoSec Medical's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Total Stockholders Equity Chart

OncoSec Medical Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Total Stockholders Equity

Get a 7-Day Free Trial

22.92

24.28

13.87

38.08

6.12

OncoSec Medical Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23
Total Stockholders Equity	Get a 7-Day Free Trial															19.82	13.89	6.12	-0.98	-5.49

OncoSec Medical (OTCPK:ONCSQ) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

OncoSec Medical's Book Value per Share for the quarter that ended in Jan. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-5.486	-	0)	/	2.9712
	=	-1.85

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

OncoSec Medical's Debt-to-Equity for the quarter that ended in Jan. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.338	+	2.127)	/	-5.486
	=	-0.63

OncoSec Medical Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSec Medical (OncoSec Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (OTCPK:ONCSQ) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

24 North Main Street, Pennington, NJ, USA, 08534

Website

https://www.oncosec.com

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

Executives

Robert J Delaversano	officer: Principal Accounting Officer	217 W. MAIN STREET, SOMERVILLE NJ 08876
Spahr Stephany Foster	director	C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Robert H. Arch	officer: President and CEO	C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
George Chi	officer: Chief Financial Officer	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Lin Shi	director	24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Yuhang Zhao	director	6 HORTON DR., CHESTER NJ 07930
Brian A Leuthner	officer: Chief Operating Officer	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Daniel J. O'connor	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
China Grand Pharmaceutical & Healthcare Holdings Ltd	10 percent owner, other: See Remarks	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Alpha Holdings, Inc.	director, 10 percent owner	GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016
Kellie Malloy Foerter	officer: Chief Operating Officer	C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218
Herbert Kim Lyerly	director	C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Chao Zhou	director	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Grand Decade Developments Ltd	10 percent owner, other: See Remarks	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000